Mucosal IL-4R antagonist HIV vaccination with SOSIP-gp140 booster can induce high-quality cytotoxic CD4

AIDS Vaccines / pharmacology Animals CD4-Positive T-Lymphocytes / immunology CD8-Positive T-Lymphocytes / immunology Immunity, Cellular / drug effects Immunity, Humoral / drug effects Immunization, Secondary Interleukin-4 Receptor alpha Subunit / antagonists & inhibitors Macaca nemestrina env Gene Products, Human Immunodeficiency Virus / pharmacology

Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
16 12 2020
Historique:
received: 03 09 2020
accepted: 02 12 2020
entrez: 17 12 2020
pubmed: 18 12 2020
medline: 29 4 2021
Statut: epublish

Résumé

Inducing humoral, cellular and mucosal immunity is likely to improve the effectiveness of HIV-1 vaccine strategies. Here, we tested a vaccine regimen in pigtail macaques using an intranasal (i.n.) recombinant Fowl Pox Virus (FPV)-gag pol env-IL-4R antagonist prime, intramuscular (i.m.) recombinant Modified Vaccinia Ankara Virus (MVA)-gag pol-IL-4R antagonist boost followed by an i.m SOSIP-gp140 boost. The viral vector-expressed IL-4R antagonist transiently inhibited IL-4/IL-13 signalling at the vaccination site. The SOSIP booster not only induced gp140-specific IgG, ADCC (antibody-dependent cellular cytotoxicity) and some neutralisation activity, but also bolstered the HIV-specific cellular and humoral responses. Specifically, superior sustained systemic and mucosal HIV Gag-specific poly-functional/cytotoxic CD4

Identifiants

DOI: 10.1038/s41598-020-79172-7 PMID: 33328567 PMC: PMC7744512
pubmed: 33328567
doi: 10.1038/s41598-020-79172-7
pii: 10.1038/s41598-020-79172-7
pmc: PMC7744512
doi:

Substances chimiques

AIDS Vaccines 0
Interleukin-4 Receptor alpha Subunit 0
env Gene Products, Human Immunodeficiency Virus 0
gp140 envelope protein, Human immunodeficiency virus 1 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

22077

Références

J Immunol. 2017 Jul 15;199(2):816-826
pubmed: 28615419
Vaccine. 2009 Nov 5;27(47):6605-12
pubmed: 19712773
Hum Vaccin. 2010 Oct;6(10):835-40
pubmed: 20864808
J Virol. 2015 Mar;89(6):3380-95
pubmed: 25589637
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10501-6
pubmed: 18650390
Expert Rev Vaccines. 2008 Apr;7(3):303-9
pubmed: 18393600
Sci Transl Med. 2012 Feb 29;4(123):123ra25
pubmed: 22378925
Proc Natl Acad Sci U S A. 2015 Mar 3;112(9):E992-9
pubmed: 25681373
Lancet HIV. 2020 Mar;7(3):e161
pubmed: 32142713
Semin Immunol. 2018 Oct;39:14-21
pubmed: 29801750
Vaccine. 2005 Oct 10;23(42):5009-21
pubmed: 15985317
Blood. 2006 Apr 15;107(8):3258-64
pubmed: 16373659
AIDS. 2006 Jan 9;20(2):294-7
pubmed: 16511428
PLoS Pathog. 2007 Jul;3(7):e94
pubmed: 17616974
Virology. 2014 Nov;468-470:479-489
pubmed: 25261870
J Virol. 2001 Aug;75(16):7435-52
pubmed: 11462016
AIDS Rev. 2003 Oct-Dec;5(4):245-52
pubmed: 15012003
Virology. 2005 Mar 15;333(2):226-38
pubmed: 15721357
J Virol. 2015 Aug;89(15):7494-505
pubmed: 25972560
J Virol. 2005 Feb;79(4):2097-107
pubmed: 15681412
Sci Rep. 2019 Apr 5;9(1):5661
pubmed: 30952887
J Virol. 2010 Oct;84(19):10354-65
pubmed: 20668079
Vaccine. 2006 Jul 26;24(31-32):5881-95
pubmed: 16759767
J Immunol. 2011 Oct 1;187(7):3555-64
pubmed: 21880986
J Immunol. 2002 Jun 1;168(11):5954-8
pubmed: 12023402
Cell. 2020 Nov 25;183(5):1340-1353.e16
pubmed: 33096020
J Virol. 2011 Sep;85(18):9334-45
pubmed: 21752903
J Virol. 2014 Jul;88(13):7357-66
pubmed: 24741089
J Virol. 2015 May;89(10):5318-29
pubmed: 25740988
Expert Rev Vaccines. 2009 Sep;8(9):1171-81
pubmed: 19722891
Viruses. 2018 Apr 23;10(4):
pubmed: 29690575
PLoS One. 2014 Feb 20;9(2):e89010
pubmed: 24586481
Nat Rev Immunol. 2020 Sep;20(9):529-536
pubmed: 32728222
PLoS One. 2013;8(4):e60420
pubmed: 23565245
Blood. 2009 Apr 23;113(17):3978-89
pubmed: 19109229
Curr Opin HIV AIDS. 2011 May;6(3):202-7
pubmed: 21399497
Immunol Rev. 2017 Jan;275(1):161-182
pubmed: 28133806
Proc Natl Acad Sci U S A. 1989 Mar;86(5):1624-8
pubmed: 2922401
J Virol. 1995 Jun;69(6):3949-54
pubmed: 7745752
Eur J Immunol. 2018 Jul;48(7):1153-1163
pubmed: 29569714
Proc Natl Acad Sci U S A. 2012 Dec 11;109(50):E3503-12
pubmed: 23151505
N Engl J Med. 2012 Apr 5;366(14):1275-86
pubmed: 22475592
Vaccine. 2011 Jul 26;29(33):5399-406
pubmed: 21651938
Expert Rev Vaccines. 2012 Mar;11(3):367-79
pubmed: 22380827
Science. 2007 Mar 16;315(5818):1583-6
pubmed: 17363674
N Engl J Med. 2013 Nov 28;369(22):2083-92
pubmed: 24099601
Vaccine. 2011 Apr 5;29(16):3008-20
pubmed: 21352941
Front Immunol. 2017 Jan 23;8:19
pubmed: 28167943
Science. 2015 Jul 10;349(6244):aac4223
pubmed: 26089353
PLoS One. 2014 Aug 29;9(8):e105366
pubmed: 25170620
J Virol. 2008 Jul;82(13):6434-46
pubmed: 18434400
MAbs. 2017 Apr;9(3):550-566
pubmed: 27996375
J Acquir Immune Defic Syndr (1988). 1993 Jan;6(1):7-14
pubmed: 8417177
Sci Rep. 2020 Jan 23;10(1):1017
pubmed: 31974500
Nature. 2002 Jan 17;415(6869):335-9
pubmed: 11797012
PLoS Pathog. 2018 Feb 23;14(2):e1006913
pubmed: 29474444
N Engl J Med. 2009 Dec 3;361(23):2209-20
pubmed: 19843557
J Virol. 2013 Jul;87(13):7445-62
pubmed: 23616666
Front Immunol. 2018 Dec 13;9:2874
pubmed: 30619259
J Virol. 1999 Sep;73(9):7524-32
pubmed: 10438842
PLoS Pathog. 2013 Sep;9(9):e1003618
pubmed: 24068931
J Virol. 2014 Aug;88(15):8242-55
pubmed: 24829343
AIDS. 2013 Feb 20;27(4):519-28
pubmed: 23364441
NPJ Vaccines. 2018 Mar 12;3:10
pubmed: 29560282
Vaccine. 2019 Feb 28;37(10):1266-1276
pubmed: 30733092
Vaccine X. 2019 Jul 16;2:100035
pubmed: 31384749
Cytokine Growth Factor Rev. 2014 Aug;25(4):437-42
pubmed: 25159217
Vaccine. 2008 Jun 13;26(25):3162-74
pubmed: 18502003
Vaccine. 2005 Mar 31;23(19):2522-9
pubmed: 15752839
J Exp Med. 2008 Jan 21;205(1):7-12
pubmed: 18195078
BMC Immunol. 2014 Sep 24;15:36
pubmed: 25245659
Clin Exp Vaccine Res. 2017 Jan;6(1):15-21
pubmed: 28168169
Curr Protoc Mol Biol. 2001 May;Chapter 16:Unit16.18
pubmed: 18265125
J Virol. 2018 Sep 12;92(19):
pubmed: 30021898
Immunol Lett. 1999 Mar;66(1-3):9-14
pubmed: 10203028
Blood. 2006 Jun 15;107(12):4781-9
pubmed: 16467198
J Clin Invest. 2019 Jan 2;129(1):182-191
pubmed: 30475230
PLoS Pathog. 2008 May 02;4(5):e1000055
pubmed: 18451982
Mucosal Immunol. 2013 Nov;6(6):1068-80
pubmed: 23403475
J Virol. 2013 Apr;87(8):4146-60
pubmed: 23345519
Cell. 2015 Dec 17;163(7):1702-15
pubmed: 26687358
Vaccine. 2014 Sep 29;32(43):5703-14
pubmed: 25151041
J Virol. 2013 Nov;87(21):11884-93
pubmed: 23986597
Virology. 2008 Nov 10;381(1):106-15
pubmed: 18793787
Blood. 2009 Jun 18;113(25):6351-60
pubmed: 19389882
Vaccine. 2006 Feb 27;24(9):1378-88
pubmed: 16257479
Vaccine. 2016 Oct 17;34(44):5251-5261
pubmed: 27639281
J Immunol. 2007 Feb 15;178(4):2370-9
pubmed: 17277143
Nat Med. 1997 Feb;3(2):205-11
pubmed: 9018240
PLoS One. 2010 Sep 16;5(9):
pubmed: 20862289
Curr Opin HIV AIDS. 2016 Nov;11(6):607-613
pubmed: 27537673

Auteurs

Z Li (Z)

Molecular Mucosal Vaccine Immunology Group, Department of Immunology and Infectious Disease, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, 2601, Australia.

M Khanna (M)

Molecular Mucosal Vaccine Immunology Group, Department of Immunology and Infectious Disease, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, 2601, Australia.
Department of Microbiology, Immunology and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA, 70112, USA.

S L Grimley (SL)

Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, 3010, Australia.

P Ellenberg (P)

Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, 3010, Australia.

C A Gonelli (CA)

Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, 3010, Australia.

Wen Shi Lee (WS)

Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, 3010, Australia.

T H Amarasena (TH)

Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, 3010, Australia.

A D Kelleher (AD)

Immunovirology and Pathogenesis Program, Kirby Institute, University of New South Wales, Sydney, NSW, 2052, Australia.

D F J Purcell (DFJ)

Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, 3010, Australia.

S J Kent (SJ)

Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, 3010, Australia. skent@unimelb.edu.au.

C Ranasinghe (C)

Molecular Mucosal Vaccine Immunology Group, Department of Immunology and Infectious Disease, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, 2601, Australia. Charani.Ranasinghe@anu.edu.au.

Articles similaires

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Use of organic material provided by an automatic enrichment device by weaner pigs and its influence on tail lesions.

Philipp Heseker, Jeanette Probst, Stefanie Ammer et al.
1.00
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH

questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Vaccins antiviraux › Vaccins contre le SIDA › Mucosal IL-4R antagonist HIV vaccination with...
questionsmedicales.fr › Eucaryotes › Animaux › Mucosal IL-4R antagonist HIV vaccination with...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD4+ › Mucosal IL-4R antagonist HIV vaccination with...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD8+ › Mucosal IL-4R antagonist HIV vaccination with...
questionsmedicales.fr › Phénomènes du système immunitaire › Immunité › Immunité acquise › Immunité cellulaire › Mucosal IL-4R antagonist HIV vaccination with...
questionsmedicales.fr › Phénomènes du système immunitaire › Immunité › Immunité acquise › Immunité humorale › Mucosal IL-4R antagonist HIV vaccination with...
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Rappel de vaccin › Mucosal IL-4R antagonist HIV vaccination with...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs immunologiques › Récepteurs aux cytokines › Récepteurs aux interleukines › Récepteurs à l'interleukine-13 › Récepteur à l'interleukine-4 de type II › Sous-unité alpha du récepteur à l'interleukine-4 › Mucosal IL-4R antagonist HIV vaccination with...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Cercopithecidae › Cercopithecinae › Macaca › Macaca nemestrina › Mucosal IL-4R antagonist HIV vaccination with...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines virales › Protéines virales structurales › Protéines de l'enveloppe virale › Produits du gène env › Produits du gène env du virus de l'immunodéficience humaine › Mucosal IL-4R antagonist HIV vaccination with...